SMO and non-small cell lung carcinoma: Our data strongly indicate that the SBE selectively and significantly targets SMO, the key regulator of SHH signaling, to repress the intensity of entire SHH pathway for inhibition of NSCLC progression and chemo-resistance developed from DPP treatment clinically.